Togo has eliminated Lymphatic filariasis (LF) from being a public health problem. The historic achievement, which comes after decades of persistent efforts has been applauded by many institutions among them GlaxoSmithKline plc (ADR)(NYSE:GSK) and the World Health Organization. The country becomes the first entity in the sub-Saharan to achieve the global target established by the 50th World Health Assembly.
The elimination was authenticated by WHO in 2015 after 15 years of campaigning by Togo in all affected districts and areas, which resulted in a 5-year surveillance phase in 2010. The country now joins another 5 countries in the Western Pacific Region, two in Southeast Asia Region. However, there are still another 33 countries that are yet to heed the calling of submitting to the same achievement.
The country has banished a significant cause of poverty
The debilitating disease, which is caused by a parasitic infection, affects people living in tropical countries. WHO estimates that close to 120 million people are infected given that it is found in 73 countries. The World Health Organization (WHO) Regional Director for Africa, Dr. Matshidiso Moeti says that the Togolese government, partners, and communities have displayed the meaning of collective commitment in banishing lymphatic filariasis—also known as elephantiasis.
Acclaiming the country’s success, Dr. Margaret Chan, the Director-General of WHO outlined, “This achievement is the culmination of more than a decade of accelerated efforts of governments, development partners, and donors, supported by WHO.”
Reaffirmation of the government’s commitment to improving healthcare
WHO works hand in hand with the likes of AFRO and ESPEN I supporting member states to get rid of the Africa Region of diseases of poverty. Moeti says they are committed to providing technical support as well as advocacy for increased funding, which perhaps entice the remaining 33 countries.
On the other hand, Togo, through its Minister of Health and Social Protection, Professor Moustafa Mijiyawa has reaffirmed its commitment to providing care to people suffering from ongoing health problems, that may have been caused by an earlier infection.
In the meantime, GSK’s stock closed at $41.28 a decline of $0.56 or 1.34%.
